|16th February 2021||Thomas Gad||4,000||Open or private sale||$47.09||$188,366.80|
|16th February 2021||Thomas Gad||7,000||Open or private sale||$47.08||$329,555.80|
|16th February 2021||Thomas Gad||7,000||Exercise of derivative||$2.00||$14,000.00|
|9th February 2021||James Healy||450,000||Open or private purchase||$20.00||$9,000,000.00|
|9th February 2021||James Healy||1,200,228||Conversion of derivative||$0.00|
|9th February 2021||James Healy||1,104,209||Conversion of derivative||$0.00|
|19th January 2021||David N Gill||2,000||Exercise of derivative||$11.16||$22,320.00|
|19th January 2021||Thomas Gad||7,000||Exercise of derivative||$2.00||$14,000.00|
|19th January 2021||David N Gill||2,000||Open or private sale||$46.52||$93,045.20|
|19th January 2021||Thomas Gad||4,000||Open or private sale||$46.56||$186,230.40|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Y-mAbs Therapeutics is a clinical-stage biopharmaceutical company. It develops novel antibody therapeutics for oncology targets. The company's services include discovery, protein engineering, clinical and regulatory.